Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter

RECENT NEWS

Coronavirus: America’s drug supply needs a refill

Coronavirus: America’s drug supply needs a refill

The coronavirus outbreak that originated in China could put the health of millions of Americans at risk — but not in the ...  Read more

Are we close to a coronavirus medical breakthrough?

Are we close to a coronavirus medical breakthrough?

Center For Medicine Public Interest Peter Pitts joins Trace Gallagher to give his insight into coronavirus treatments. ...  Read more

Coronavirus sweeping across the U.S.

Coronavirus sweeping across the U.S.

Peter Pitts joins National Report to discuss social distancing...  Read more

DRUGWONKS BLOG